Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Harris, Randall E ^a   Beebe Donk, Joanne ^a   Alshafie, Galal A ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; INDOMETACIN; MELOXICAM; NAPROXEN; NON PRESCRIPTION DRUG; PARACETAMOL; PROSTAGLANDIN; ROFECOXIB; VALDECOXIB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG APPROVAL; DRUG EXPOSURE; DRUG SELECTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION;

EID: 33144481709     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-27     Document Type: Article

References (26)

1. Couzin J: Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science 2004, 306:384-385.
2. Couzin J: Clinical Trials: Nail-biting time for trials of drugs. Science 2004, 306:1673-1675.
3. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc 2001, 286(8):954-959.
4. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005. 352(II):1092-1102.
5. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352(II):1071-1080.
6. White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM, Geis GS, Lefkowith JB: Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002, 89(4):425-430.
7. White WB, Faich G, Borer JS, Makuch RW: Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor, celecoxib. Am J Cardiol 2003, 92(4):411-418.
8. Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q: Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 2002, 89(2):204-209.
9. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupaci A: Effect of selective cyclooxygenase-2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003, 163(4):481-486.
10. Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullin CD: Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med 2005, 165(2):181-186.
11. Cancer Statistics, Incidence and Mortality. American Cancer Society 2004.
12. Harris RE, Beebe-Donk J, Doss H, Burr-Doss D: Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (Review). Oncology Reports 2004, 13:559-583.
13. Schlesselman JJ: Case Control Studies Oxford University Press, New York. 1982.
14. Harrell F: Logistic Regression Procedure. Statistical Analysis System (SAS) 2005.
15. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971, 23 323-325.
16. Herschman HR: Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer and Metos Rev 1994, 13:241-256.
17. Hla T, Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992, 89:7384-7388.
18. Harris RE: Epidemiology of breast cancer and nonsteroidal anti-inflammatory drugs. In COX-2 Blockade in Cancer Prevention and Therapy Edited by: Harris RE Humana Press, Totowa, NJ; 2002:57-68.
19. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM: Cyclooxygenase-2 gene expression in human breast cancer. International Journal of Oncology 1997, 10:503-507.
20. Masferrer JL, Leahy KM, Koki AT, Aweifell BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000, 60(5):1306-1311.
21. Abou-Issa HM, Alshafie GA, Harris RE: Chemoprevention of breast cancer by nonsteroidal anti-inflammatory drugs and selective COX-2 blockade in animals. In COX-2 Blockade in Cancer Prevention and Therapy Edited by. Harris RE. Humana Press, Totowa, NJ; 2002:85-98.
22. Harris RE, Alshafie GA, Abou-Issa H, Seibert K: Chemoprevention of breast cancer in rats by Celecoxib, a specific cyclooygenase-2 (COX-2) inhibitor. Cancer Res 2000, 60:2101-2103.
23. Harris RE, Robertson FM, Farrar WB, Brueggemeier RW. Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP-19): an extension of the dietary tat hypothesis of breast cancer. Medical Hypotheses 1999, 52(4):292-293.
24. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen blosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996, 137(12):5739-5742.
25. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM: Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Letters 1999, 140(1-2):27-35.
26. Harris RE: Does the dose make the poison? Science 2005, 308:203.